Arif Bilal — SEC Form 4 filings
SEC reporting owner CIK 1959750. 13 Form 4 filings on record with FilingPulse; latest filed 2026-06-11.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-03-05 to 2026-06-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 8 legs across 2 filings — 13,757 shares, $2,175,568 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 28.
- Largest priced transaction: sale of 5,580 shares @ $162.31 ($905,690) in Sarepta Therapeutics, Inc., filed 2024-06-25.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | Chief Tech Ops Officer | 10 | — | 8 legs · 13,757 sh · $2,175,568 | 24 |
| KalVista Pharmaceuticals, Inc. (KALV) | Chief Operations Officer | 3 | — | — | 4 |
Form 4 filings — Arif Bilal
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-11 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 49,000 (derivative) | EDGAR |
| 2026-01-21 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 49,000 (derivative) @ $0 | EDGAR |
| 2025-10-08 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-08-06 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Grant/award (A): 6,250 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Tax withholding (F): 523 @ $100.13 · Grant/award (A): 8,276 · Grant/award (A): 16,644 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Option exercise (M): 17,500 · Tax withholding (F): 508 @ $103.70 · Tax withholding (F): 8,527 @ $103.70 · Option exercise (M): 17,500 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Tax withholding (F): 281 @ $101.34 · Tax withholding (F): 233 @ $101.34 | EDGAR |
| 2025-03-04 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Tax withholding (F): 719 @ $103.77 | EDGAR |
| 2025-02-13 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Grant/award (A): 3,500 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Option exercise (M): 6,250 · Tax withholding (F): 2,352 @ $164.64 · Sale (S): 5,580 @ $162.31 · Sale (S): 1,055 @ $163.83 · Sale (S): 300 @ $164.61 · Sale (S): 700 @ $166.10 · +4 more | EDGAR |
| 2024-03-11 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Tax withholding (F): 506 @ $120.49 · Tax withholding (F): 472 @ $123.14 | EDGAR |
| 2024-03-06 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Tax withholding (F): 285 @ $125.32 · Tax withholding (F): 237 @ $125.32 | EDGAR |
| 2024-03-05 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Tax withholding (F): 251 @ $126.19 · Grant/award (A): 6,000 @ $0 · Sale (S): 1,543 @ $128.58 · Sale (S): 457 @ $129.71 · Tax withholding (F): 114 @ $126.19 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1959750 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →